Ask AI
ProCE Banner Activity

Available Antibody-Drug Conjugates for R/R DLBCL: A Summary Resource 

PDF

Download this resource for healthcare professionals with a brief overview of available antibody-drug conjugates approved for use in patients with relapsed/refractory diffuse large B-cell lymphoma. 

Released: January 06, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from ADC Therapeutics and Pfizer Inc.

ADC Therapeutics

Pfizer, Inc.

Target Audience

This activity is intended for community teams caring for patients with DLBCL, including hematologists/oncologists, nurse practitioners, physician associates, pharmacists, nurses, and other healthcare professionals. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the potential of novel antibody-drug conjugates to address unmet needs for patients with R/R DLBCL

  • Develop individualized treatment protocols for patients with R/R DLBCL based on the latest clinical data, guidelines, and patient-specific factors

  • Formulate multidisciplinary strategies to identify, prevent, and manage toxicities associated with antibody-drug conjugates for R/R DLBCL

  • Incorporate patient goals and preferences into shared decision-making to optimize R/R DLBCL treatment planning across the continuum of care

Disclosure

Primary Author

Brad Kahl, MD: consultant/advisor/speaker: AbbVie, ADCT, AstraZeneca, BeOne, Bristol Myers Squibb, Genentech, Incyte, Lilly, Merck, Pfizer, Roche.